Solid Tumor
Information
- Disease name
- Solid Tumor
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00479128 | Active, not recruiting | Phase 1 | Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | September 28, 2006 | September 30, 2024 |
| NCT04641871 | Active, not recruiting | Phase 1 | Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies | October 12, 2020 | June 2024 |
| NCT04939610 | Active, not recruiting | Phase 1/Phase 2 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) | July 30, 2021 | June 30, 2028 |
| NCT05162755 | Active, not recruiting | Phase 1 | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers | October 15, 2021 | July 31, 2024 |
| NCT04455620 | Active, not recruiting | Phase 1/Phase 2 | BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors | January 26, 2021 | May 31, 2024 |
| NCT05494762 | Active, not recruiting | Phase 1 | Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors | August 25, 2022 | January 31, 2025 |
| NCT05169437 | Active, not recruiting | Phase 2 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | March 15, 2022 | January 1, 2025 |
| NCT02974738 | Active, not recruiting | Phase 1 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | December 7, 2016 | April 14, 2025 |
| NCT02193503 | Active, not recruiting | Phase 1 | MVX-ONCO-1 in Patients With Solid Tumor | March 2014 | December 2026 |
| NCT04659629 | Active, not recruiting | Phase 1 | NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | April 26, 2021 | August 2024 |
| NCT04690699 | Active, not recruiting | Phase 1/Phase 2 | LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors | August 1, 2021 | May 2025 |
| NCT03006172 | Active, not recruiting | Phase 1 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | December 13, 2016 | November 30, 2024 |
| NCT04205227 | Active, not recruiting | Phase 1/Phase 2 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | February 18, 2020 | March 31, 2026 |
| NCT03013218 | Active, not recruiting | Phase 1 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | February 3, 2017 | December 1, 2024 |
| NCT04078152 | Active, not recruiting | Phase 4 | Durvalumab Long-Term Safety and Efficacy Study | September 5, 2019 | September 30, 2024 |
| NCT04344795 | Active, not recruiting | Phase 1 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | May 6, 2020 | October 1, 2024 |
| NCT03975387 | Active, not recruiting | Phase 1/Phase 2 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | July 11, 2019 | June 30, 2025 |
| NCT04410224 | Active, not recruiting | Phase 1 | Study of ASN004 in Patients With Advanced Solid Tumors | April 8, 2022 | September 30, 2024 |
| NCT03944499 | Active, not recruiting | Phase 1 | Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. | October 11, 2019 | June 2025 |
| NCT05787964 | Active, not recruiting | Immunity to Infection in Healthy Participants and Participants With Cancer | October 1, 2022 | September 1, 2024 | |
| NCT03839342 | Active, not recruiting | Phase 2 | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations | June 7, 2019 | December 2024 |
| NCT00638898 | Active, not recruiting | Phase 1 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | February 26, 2007 | December 30, 2024 |
| NCT05990920 | Active, not recruiting | Phase 1 | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | August 23, 2023 | December 2024 |
| NCT05009329 | Active, not recruiting | Phase 1/Phase 2 | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | July 26, 2021 | December 2025 |
| NCT06116240 | Active, not recruiting | Phase 1 | A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors | September 2, 2022 | December 2023 |
| NCT02608385 | Active, not recruiting | Phase 1 | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | December 2015 | November 2026 |
| NCT05716919 | Active, not recruiting | Phase 1 | Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule | March 9, 2023 | December 2023 |
| NCT03977467 | Active, not recruiting | Phase 2 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | August 30, 2019 | July 2024 |
| NCT04363242 | Active, not recruiting | Phase 1 | A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions | April 9, 2020 | September 30, 2023 |
| NCT04050709 | Active, not recruiting | Phase 1 | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | July 18, 2019 | December 30, 2024 |
| NCT02320435 | Active, not recruiting | Phase 3 | A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | February 2, 2015 | December 31, 2025 |
| NCT05702424 | Active, not recruiting | Phase 1 | Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | January 10, 2023 | March 2026 |
| NCT05037149 | Active, not recruiting | Phase 1 | Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors | November 1, 2021 | March 30, 2024 |
| NCT03775525 | Active, not recruiting | Phase 1 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | March 1, 2019 | December 2023 |
| NCT04731467 | Active, not recruiting | Phase 1/Phase 2 | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | March 19, 2021 | January 2025 |
| NCT04780217 | Active, not recruiting | Phase 1/Phase 2 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | August 10, 2021 | August 2025 |
| NCT04280081 | Active, not recruiting | Phase 2 | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation | March 16, 2020 | November 20, 2025 |
| NCT05199272 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | December 29, 2021 | March 2025 |
| NCT05205330 | Active, not recruiting | Phase 1/Phase 2 | A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | November 23, 2021 | December 2024 |
| NCT03865082 | Active, not recruiting | Phase 2 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | October 29, 2019 | April 2022 |
| NCT03570619 | Active, not recruiting | Phase 2 | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | December 14, 2018 | December 2024 |
| NCT02041416 | Active, not recruiting | Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers | May 15, 2013 | December 1, 2024 | |
| NCT04937153 | Active, not recruiting | Phase 1 | GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | June 15, 2021 | November 12, 2024 |
| NCT03207672 | Active, not recruiting | Phase 1 | Study of E7389 Liposomal Formulation in Participants With Solid Tumor | August 18, 2017 | August 31, 2025 |
| NCT04074967 | Active, not recruiting | Phase 1/Phase 2 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | June 11, 2020 | November 21, 2027 |
| NCT02791334 | Active, not recruiting | Phase 1 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | June 29, 2016 | July 2024 |
| NCT03560882 | Active, not recruiting | Phase 1 | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | July 19, 2018 | August 1, 2025 |
| NCT04800822 | Active, not recruiting | Phase 1 | PF-07284892 in Participants With Advanced Solid Tumors | March 17, 2021 | November 29, 2025 |
| NCT04672434 | Active, not recruiting | Phase 1 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | November 19, 2020 | December 2024 |
| NCT04101357 | Active, not recruiting | Phase 1/Phase 2 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | June 19, 2020 | July 2024 |
| NCT03774979 | Active, not recruiting | Phase 1 | SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors | January 24, 2019 | December 2023 |
| NCT02846038 | Active, not recruiting | Understanding Communication in Healthcare to Achieve Trust (U-CHAT) | September 9, 2016 | September 2024 | |
| NCT02861300 | Active, not recruiting | Phase 1/Phase 2 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | September 12, 2016 | December 2023 |
| NCT04552288 | Active, not recruiting | Phase 2 | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | September 16, 2020 | March 16, 2025 |
| NCT03307785 | Active, not recruiting | Phase 1 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | October 12, 2017 | August 30, 2024 |
| NCT04827576 | Active, not recruiting | Phase 2 | Study of Magrolimab in Patients With Solid Tumors | October 1, 2021 | March 2025 |
| NCT05323045 | Active, not recruiting | Phase 1 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | March 21, 2022 | July 2024 |
| NCT05219734 | Active, not recruiting | MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment | November 29, 2021 | December 2026 | |
| NCT05228015 | Active, not recruiting | Phase 1 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | January 7, 2022 | June 2025 |
| NCT05322408 | Active, not recruiting | Phase 1 | HCW9218 in Select Advanced Solid Tumors | April 1, 2022 | February 2026 |
| NCT03875287 | Active, not recruiting | Phase 1 | Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors | April 17, 2019 | December 2024 |
| NCT03364400 | Active, not recruiting | Phase 1 | Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors | November 28, 2017 | June 2024 |
| NCT03396445 | Active, not recruiting | Phase 1 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | February 18, 2018 | October 25, 2024 |
| NCT04304066 | Active, not recruiting | N/A | Research for the Molecular Imaging of the PD-L1 Targeting Tracer | August 6, 2019 | December 2024 |
| NCT03447470 | Active, not recruiting | Phase 1 | Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | March 18, 2019 | September 29, 2023 |
| NCT04570839 | Active, not recruiting | Phase 1/Phase 2 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | August 31, 2020 | August 2024 |
| NCT03493945 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) | May 1, 2018 | December 31, 2024 |
| NCT02909777 | Active, not recruiting | Phase 1 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | October 2016 | July 2024 |
| NCT05250284 | Active, not recruiting | The Intersection of Oncology Care and Worker Well-Being | April 4, 2022 | August 2025 | |
| NCT05103358 | Active, not recruiting | Phase 2 | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | February 15, 2022 | December 31, 2025 |
| NCT02932280 | Active, not recruiting | Phase 1/Phase 2 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | October 2016 | October 2024 |
| NCT02937272 | Active, not recruiting | Phase 1 | A Study of LY3200882 in Participants With Solid Tumors | November 21, 2016 | August 1, 2024 |
| NCT01428141 | Completed | Phase 1 | A Phase I Study of E7050 in Subjects With Solid Tumors | September 2011 | July 2013 |
| NCT01432951 | Completed | Phase 1 | A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma | November 2011 | January 5, 2018 |
| NCT01463982 | Completed | Phase 1 | Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies | December 2010 | December 2013 |
| NCT01468922 | Completed | Phase 1 | Pazopanib and ARQ 197 for Advanced Solid Tumors | January 23, 2012 | February 11, 2016 |
| NCT01473095 | Completed | Phase 1 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | November 2011 | August 7, 2017 |
| NCT01540175 | Completed | Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant | March 2012 | June 2015 | |
| NCT01585623 | Completed | Phase 1 | Drug Interaction Study of SAR302503 in Patients With Solid Tumor | June 2012 | March 2013 |
| NCT01588522 | Completed | Phase 1 | Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | July 2012 | March 2017 |
| NCT01596140 | Completed | Phase 1 | Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | December 18, 2012 | June 1, 2020 |
| NCT01607905 | Completed | Phase 1 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | June 18, 2012 | March 15, 2016 |
| NCT01639950 | Completed | Validating Pain Scales in Children and Young Adults | August 6, 2012 | ||
| NCT01648764 | Completed | Phase 1 | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | September 2008 | November 2012 |
| NCT01682135 | Completed | Phase 1 | A Study in Participants With Advanced Solid Tumors | November 2012 | March 2015 |
| NCT01683149 | Completed | Phase 1 | Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies | January 2013 | January 2016 |
| NCT01705002 | Completed | Phase 1 | Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | October 2012 | June 2018 |
| NCT01752920 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | December 10, 2012 | August 28, 2018 |
| NCT01773434 | Completed | Phase 1 | A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103) | December 2012 | October 2016 |
| NCT01798654 | Completed | EUS-FNA for Patients With Antithrombotic Agents | September 2012 | ||
| NCT06039137 | Completed | The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment | June 1, 2022 | October 31, 2023 | |
| NCT01833546 | Completed | Phase 1 | A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | April 18, 2013 | January 25, 2016 |
| NCT01840579 | Completed | Phase 1 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | April 26, 2013 | February 28, 2020 |
| NCT01848834 | Completed | Phase 1 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | May 7, 2013 | June 30, 2020 |
| NCT01875705 | Completed | Phase 1 | A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | June 21, 2013 | September 23, 2016 |
| NCT01954355 | Completed | Phase 1 | LDE225 and Paclitaxel in Solid Tumors | September 2013 | November 2016 |
| NCT01957735 | Completed | Phase 1 | BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors | October 2013 | February 1, 2017 |
| NCT01967043 | Completed | Phase 1 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies | October 2013 | September 2016 |
| NCT01971515 | Completed | Phase 1 | First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies | December 13, 2013 | August 9, 2018 |
| NCT02030067 | Completed | Phase 1/Phase 2 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | December 2013 | December 2019 |
| NCT02048709 | Completed | Phase 1 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | April 2014 | February 2016 |
| NCT02054806 | Completed | Phase 1 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | February 17, 2014 | April 30, 2021 |
| NCT02065297 | Completed | Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD) | July 28, 2009 | ||
| NCT02076230 | Completed | Phase 1 | A Phase 1 TH-302 Mass Balance Trial | February 2014 | March 2016 |
| NCT02132754 | Completed | Phase 1 | Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | June 27, 2014 | July 31, 2019 |
| NCT02150733 | Completed | Phase 1 | Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | April 2014 | July 2016 |
| NCT05914142 | Completed | N/A | Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tumors | December 15, 2022 | July 4, 2023 |
| NCT02161978 | Completed | Vascular Dysfunction and Antiangiogenic Therapy | February 9, 2012 | December 12, 2018 | |
| NCT02199548 | Completed | The Good Patient Study | July 2014 | May 2015 | |
| NCT02216409 | Completed | Phase 1 | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | August 2014 | December 2018 |
| NCT02232243 | Completed | Phase 1 | HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors | July 2015 | December 1, 2018 |
| NCT02250157 | Completed | Phase 1 | A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies | September 5, 2014 | March 4, 2020 |
| NCT02250170 | Completed | Phase 1 | Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor | October 23, 2014 | March 8, 2019 |
| NCT05898451 | Completed | Phase 2 | Effect of Refnot on Immunity in Cancer Patients | June 4, 2009 | November 2011 |
| NCT02264613 | Completed | Phase 1/Phase 2 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | October 2014 | April 2020 |
| NCT02273739 | Completed | Phase 1/Phase 2 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | December 8, 2014 | June 3, 2016 |
| NCT02274610 | Completed | Phase 1 | Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer | November 2014 | December 2015 |
| NCT02278250 | Completed | Phase 1 | First in Human Study of M4344 in Participants With Advanced Solid Tumors | January 26, 2015 | September 24, 2021 |
| NCT02280954 | Completed | Phase 1 | Indocyanine Green for Solid Tumors | November 2013 | February 2017 |
| NCT02285738 | Completed | Early Phase 1 | Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis | December 30, 2014 | October 1, 2018 |
| NCT02289196 | Completed | Phase 1 | Safety Study of Vx006 Vaccine in Solid Tumor Patients | March 2014 | May 2017 |
| NCT00251407 | Completed | Phase 1 | Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies | September 1999 | April 2009 |
| NCT02352844 | Completed | Phase 2 | Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations | October 7, 2015 | August 15, 2017 |
| NCT02355535 | Completed | Phase 1 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | February 2015 | May 18, 2020 |
| NCT02412462 | Completed | Phase 1 | Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy | April 2015 | January 2017 |
| NCT02423343 | Completed | Phase 1/Phase 2 | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | January 1, 2015 | July 8, 2020 |
| NCT02428036 | Completed | Phase 1 | A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions | June 2015 | June 2017 |
| NCT02441543 | Completed | Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus | April 2015 | May 2018 | |
| NCT00283257 | Completed | N/A | Simultaneous Care: Linking Palliation to Clinical Trials | February 2002 | December 2013 |
| NCT02447419 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors | December 3, 2014 | December 1, 2020 |
| NCT02449538 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors | February 2015 | August 2016 |
| NCT02449564 | Completed | N/A | The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors | November 24, 2014 | November 3, 2017 |
| NCT02454010 | Completed | Phase 1 | A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer | January 2016 | October 2021 |
| NCT02466802 | Completed | Phase 1 | Study of Regorafenib and Sildenafil for Advanced Solid Tumors | July 1, 2015 | January 28, 2019 |
| NCT02471846 | Completed | Phase 1 | A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | July 28, 2015 | October 2, 2019 |
| NCT02474186 | Completed | Phase 2 | Phase II Study for Solid Metastatic Tumors | April 2003 | July 2015 |
| NCT02476123 | Completed | Phase 1 | Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors | June 2015 | December 21, 2018 |
| NCT02488330 | Completed | Phase 3 | An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | August 27, 2015 | June 29, 2018 |
| NCT02490475 | Completed | Phase 1 | A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors | February 2004 | April 2006 |
| NCT02494596 | Completed | Phase 1 | A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors | January 2004 | September 2005 |
| NCT02505165 | Completed | N/A | Illness Management and Parental Adjustment to Cancer Treatment | November 19, 2015 | February 1, 2022 |
| NCT02510001 | Completed | Phase 1 | MEK and MET Inhibition in Colorectal Cancer | November 2014 | December 3, 2018 |
| NCT02517918 | Completed | Phase 1 | Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma | February 2015 | November 16, 2021 |
| NCT00052273 | Completed | Phase 1 | LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors | December 2002 | October 2005 |
| NCT02536469 | Completed | Phase 1 | HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors | August 2015 | November 2016 |
| NCT02590952 | Completed | Phase 1 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | October 31, 2011 | April 30, 2019 |
| NCT05732350 | Completed | Exploratory Drug Interaction Study Between SMIs and DOACs | November 11, 2021 | February 29, 2024 | |
| NCT02627274 | Completed | Phase 1 | A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | December 7, 2015 | November 10, 2022 |
| NCT02640508 | Completed | Phase 2 | Eribulin and Lenvatinib in Advanced Solid Tumors | May 2016 | January 12, 2023 |
| NCT02643303 | Completed | Phase 1/Phase 2 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | December 28, 2016 | February 23, 2022 |
| NCT02648425 | Completed | Phase 1 | Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine | August 5, 2014 | September 15, 2017 |
| NCT02705105 | Completed | Phase 1/Phase 2 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | February 2016 | October 10, 2018 |
| NCT02715531 | Completed | Phase 1 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | April 6, 2016 | May 31, 2021 |
| NCT02718911 | Completed | Phase 1 | A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | June 16, 2016 | December 14, 2018 |
| NCT02730481 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies | March 2016 | May 2021 |
| NCT05547906 | Completed | Phase 1 | Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors | November 8, 2021 | February 29, 2024 |
| NCT02742935 | Completed | Phase 1 | A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects | April 27, 2016 | May 6, 2019 |
| NCT02784795 | Completed | Phase 1 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | November 4, 2016 | February 13, 2020 |
| NCT02793466 | Completed | Phase 1 | Durvalumab in Pediatric and Adolescent Patients | July 2016 | April 30, 2023 |
| NCT00333502 | Completed | Phase 1/Phase 2 | Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors | May 2006 | April 2012 |
| NCT02834052 | Completed | Phase 1/Phase 2 | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | January 10, 2018 | July 29, 2022 |
| NCT02867007 | Completed | Phase 1 | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | August 2016 | December 15, 2019 |
| NCT02876510 | Completed | Phase 1 | ACTolog in Patients With Solid Cancers | June 30, 2017 | September 22, 2021 |
| NCT02877589 | Completed | Interest of Routine Screening for Hepatitis B and C in Patients Receiving Chemotherapy for Solid Tumors | May 2012 | April 2014 | |
| NCT02884128 | Completed | Phase 1 | A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors | January 2006 | July 2010 |
| NCT02890511 | Completed | Phase 1/Phase 2 | A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer | August 2010 | October 2012 |
| NCT02953782 | Completed | Phase 1/Phase 2 | Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | November 2, 2016 | February 10, 2020 |
| NCT02959619 | Completed | Phase 1 | Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK | March 6, 2017 | April 23, 2020 |
| NCT02963389 | Completed | Phase 1 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients | October 4, 2016 | November 2018 |
| NCT02986100 | Completed | Phase 1 | Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib | November 2016 | September 2018 |
| NCT02987166 | Completed | Phase 1 | HDCRT Plus Pembrolizumab in Advanced Malignancies | March 21, 2017 | February 10, 2020 |
| NCT05440006 | Completed | Phase 1 | A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects | July 3, 2022 | July 20, 2022 |
| NCT03009292 | Completed | Phase 1 | Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor | August 6, 2018 | August 27, 2021 |
| NCT03013491 | Completed | Phase 1/Phase 2 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | January 2017 | October 6, 2021 |
| NCT03015324 | Completed | Phase 1 | Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors | August 8, 2017 | February 2, 2021 |
| NCT06456216 | Completed | Performance Evaluation of Diagnostic Accuracy of PanTum Detect Test for Detection of Solid Tumours in Known Cancer Population and in Cancer Free Population. | February 21, 2022 | October 20, 2023 | |
| NCT03027128 | Completed | Phase 1 | QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | August 2, 2017 | February 7, 2019 |
| NCT03027284 | Completed | Phase 1 | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | February 3, 2017 | March 17, 2020 |
| NCT03042910 | Completed | Phase 1 | A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors | October 13, 2016 | June 22, 2017 |
| NCT03051477 | Completed | Phase 1 | Trial of Mistletoe Extract in Patients With Advanced Solid Tumors | March 1, 2017 | August 5, 2022 |
| NCT03053466 | Completed | Phase 1 | APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | March 27, 2017 | February 25, 2022 |
| NCT03057145 | Completed | Phase 1 | Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | March 10, 2017 | June 9, 2021 |
| NCT03062982 | Completed | Phase 1 | Food-Effect and Metabolism Study in Healthy Subjects | December 21, 2016 | January 4, 2017 |
| NCT03080311 | Completed | Phase 1 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | February 12, 2017 | July 17, 2020 |
| NCT03085914 | Completed | Phase 1/Phase 2 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | May 2, 2017 | July 13, 2020 |
| NCT03087227 | Completed | N/A | Shared Health Information System for Febrile Neutropenia | February 22, 2017 | October 20, 2019 |
| NCT03099109 | Completed | Phase 1 | A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors | April 12, 2017 | August 30, 2023 |
| NCT03109639 | Completed | N/A | A Randomized Prospective Comparison of the New EUS Guided Acquire TM Needle Biopsy vs EUS Guided Fine Needle Aspiration for Suspected Solid Gastrointestinal Lesions | April 13, 2017 | November 30, 2017 |
| NCT03118817 | Completed | Phase 1 | Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers | May 19, 2017 | February 4, 2020 |
| NCT00413075 | Completed | Phase 1 | Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | June 2006 | August 2011 |
| NCT03130140 | Completed | N/A | MOSE to Improve the Diagnostic Accuracy During EUS-guided FNA Using a 19-gauge Needle for Solid Lesions | February 26, 2016 | September 1, 2018 |
| NCT05412420 | Completed | N/A | Artificial Intelligence to Search for Abnormalities in Ambulatory Cancer Patients | August 3, 2022 | October 13, 2023 |
| NCT05391022 | Completed | Phase 1 | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies | July 20, 2021 | February 29, 2024 |
| NCT03159585 | Completed | Phase 1 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | April 14, 2017 | June 4, 2019 |
| NCT03164603 | Completed | Phase 1 | NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | June 29, 2017 | September 25, 2019 |
| NCT05390710 | Completed | Phase 1 | PhI to Solid Tumors and PhII to Locally Advanced or mTNBC | June 12, 2021 | December 11, 2023 |
| NCT03181854 | Completed | N/A | Randomized Controlled Trial of Integrated Early Palliative Care | September 8, 2017 | June 30, 2019 |
| NCT05359718 | Completed | The Psychological Impact of COVID-19 on Patients With Solid Malignancies: A Single-Institution Survey Study | March 1, 2021 | September 13, 2023 | |
| NCT03195478 | Completed | Phase 1/Phase 2 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | August 2, 2017 | January 5, 2024 |
| NCT03220854 | Completed | Phase 2 | SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx | October 10, 2017 | September 22, 2021 |
| NCT05357911 | Completed | Phase 1 | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | July 13, 2021 | December 3, 2021 |
| NCT03238027 | Completed | Phase 1 | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | September 1, 2017 | November 20, 2020 |
| NCT03247309 | Completed | Phase 1 | TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) | December 19, 2018 | September 18, 2023 |
| NCT03249792 | Completed | Phase 1 | Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | September 20, 2017 | February 22, 2023 |
| NCT05357820 | Completed | Phase 1 | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK | July 19, 2021 | December 3, 2021 |
| NCT05336279 | Completed | Phase 1 | Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition | May 11, 2022 | June 20, 2022 |
| NCT03286296 | Completed | Phase 1 | LZM009 to Treat Patients With Advanced Solid Tumors | August 21, 2017 | April 23, 2019 |
| NCT03297424 | Completed | Phase 1 | A Study of PLX2853 in Advanced Malignancies. | September 12, 2017 | June 7, 2021 |
| NCT03311412 | Completed | Phase 1 | Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas | November 20, 2017 | March 23, 2022 |
| NCT03359850 | Completed | Phase 1 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | February 20, 2018 | June 24, 2020 |
| NCT03406364 | Completed | Phase 1 | Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor | June 6, 2018 | July 24, 2020 |
| NCT03447483 | Completed | N/A | Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE). | April 20, 2018 | June 18, 2020 |
| NCT03454620 | Completed | Phase 1/Phase 2 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | April 2, 2018 | January 10, 2022 |
| NCT05248074 | Completed | Phase 1 | To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers | January 4, 2022 | October 18, 2022 |
| NCT03489343 | Completed | Phase 1 | Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | May 24, 2018 | June 3, 2020 |
| NCT03489369 | Completed | Phase 1 | Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | May 8, 2018 | January 6, 2020 |
| NCT04547205 | Completed | Phase 1 | A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors | June 6, 2020 | October 31, 2022 |
| NCT04508179 | Completed | Phase 1 | A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects | October 28, 2020 | October 25, 2021 |
| NCT04122625 | Completed | Phase 1/Phase 2 | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | April 26, 2019 | April 6, 2022 |
| NCT04475523 | Completed | Phase 1 | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | September 22, 2020 | May 19, 2023 |
| NCT04144842 | Completed | Phase 1 | Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017 | December 3, 2019 | March 29, 2023 |
| NCT00781846 | Completed | Phase 1 | Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | October 2008 | February 2010 |
| NCT04422457 | Completed | N/A | Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients | June 13, 2020 | March 1, 2022 |
| NCT04172506 | Completed | Phase 1/Phase 2 | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | September 10, 2019 | January 30, 2022 |
| NCT04419623 | Completed | Phase 1 | A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer | July 9, 2020 | December 15, 2020 |
| NCT00786669 | Completed | Phase 1 | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors | October 2008 | November 2012 |
| NCT04180384 | Completed | Phase 2 | A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients | September 23, 2015 | June 15, 2021 |
| NCT04403308 | Completed | Phase 1 | ONO-7913 Phase I Study (ONO-7913) | July 28, 2020 | January 13, 2022 |
| NCT04184869 | Completed | Phase 1 | Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials | August 5, 2019 | March 31, 2023 |
| NCT00786838 | Completed | Phase 2 | A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram | October 2008 | December 2009 |
| NCT00803556 | Completed | Phase 1 | Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | January 2006 | August 2009 |
| NCT00808184 | Completed | Phase 4 | Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype | April 2010 | February 2012 |
| NCT04200963 | Completed | Phase 1 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | December 18, 2019 | July 18, 2023 |
| NCT04202705 | Completed | Phase 1 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 | February 28, 2020 | January 26, 2023 |
| NCT04400383 | Completed | Phase 1 | Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors | June 4, 2020 | September 28, 2023 |
| NCT00834704 | Completed | Phase 1 | Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | February 2009 | November 2012 |
| NCT04397575 | Completed | The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients | April 3, 2020 | September 30, 2021 | |
| NCT04235101 | Completed | Phase 1 | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | June 22, 2020 | April 24, 2023 |
| NCT04366648 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor | May 4, 2018 | March 31, 2021 |
| NCT00840190 | Completed | Phase 1 | A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies | December 2008 | September 2011 |
| NCT00847054 | Completed | Phase 1 | A Study of of MORAb-004 in Subjects With Solid Tumors | March 2009 | April 2014 |
| NCT04365413 | Completed | N/A | A Feasibility Study for the Use of Multispectral Optoacoustic Tomography in the Detection of Tumors | July 22, 2020 | December 12, 2022 |
| NCT04258527 | Completed | Phase 1 | Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations | March 26, 2020 | March 8, 2021 |
| NCT04264767 | Completed | Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA | April 17, 2019 | January 30, 2021 | |
| NCT00867295 | Completed | Phase 3 | Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device | September 2008 | March 2010 |
| NCT04351165 | Completed | Phase 1 | BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects | October 29, 2020 | April 30, 2021 |
| NCT04306224 | Completed | Phase 1 | A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas | June 5, 2020 | October 7, 2022 |
| NCT04346381 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | June 5, 2020 | June 22, 2022 |
| NCT00888108 | Completed | Phase 1 | Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer | July 2009 | March 2012 |
| NCT00894049 | Completed | Phase 2 | A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation | November 2002 | February 2013 |
| NCT00896662 | Completed | Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202 | January 2005 | August 2008 | |
| NCT00920595 | Completed | Phase 1 | Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors | June 2009 | October 2011 |
| NCT00920868 | Completed | Phase 1 | XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | May 2009 | August 2014 |
| NCT00921336 | Completed | Phase 1 | Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor | June 2009 | August 2010 |
| NCT00927966 | Completed | Phase 1 | RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms | July 2009 | January 2011 |
| NCT00955812 | Completed | Phase 1 | STAT3 Inhibitor for Solid Tumors | June 2009 | November 2012 |
| NCT00968916 | Completed | Phase 1 | Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors | September 2009 | August 2011 |
| NCT01004861 | Completed | Phase 1 | Safety Study of PLX108-01 in Patients With Solid Tumors | October 1, 2009 | October 25, 2018 |
| NCT01017731 | Completed | Phase 2 | Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes | November 2009 | May 2014 |
| NCT01041235 | Completed | Phase 1 | Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies | December 2009 | December 2011 |
| NCT01049061 | Completed | Phase 1 | A Study of MORAb-003 in Patients With Solid Tumor | January 2010 | February 2013 |
| NCT01063075 | Completed | Phase 2 | A Study in Advanced Solid Tumors | June 2010 | October 2015 |
| NCT01072266 | Completed | Phase 1 | A Dose-escalation Study in Subjects With Advanced Malignancies | January 2010 | January 2013 |
| NCT01099358 | Completed | Phase 2 | Study in Advanced Solid Tumors | April 2010 | May 2016 |
| NCT01134250 | Completed | Phase 1/Phase 2 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | August 6, 2008 | April 7, 2014 |
| NCT01141257 | Completed | Phase 1 | Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug | May 2010 | September 2011 |
| NCT01165905 | Completed | Phase 1 | Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors | January 2010 | July 2011 |
| NCT01168011 | Completed | Phase 1 | Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors | July 2010 | December 2015 |
| NCT01170897 | Completed | Phase 1 | Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors | July 2010 | January 2014 |
| NCT01184326 | Completed | Phase 1 | Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | January 2011 | March 2017 |
| NCT01225536 | Completed | Phase 1 | Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations | October 2010 | March 2013 |
| NCT01234012 | Completed | Phase 1 | Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 | May 2011 | March 2014 |
| NCT01239381 | Completed | N/A | Individualized Stereotactic Body Radiotherapy of Liver Metastases | June 2010 | September 2017 |
| NCT01240590 | Completed | Phase 1/Phase 2 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | January 26, 2011 | December 31, 2016 |
| NCT01248429 | Completed | Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases | November 2010 | February 2011 | |
| NCT01284192 | Completed | Phase 1 | Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma) | December 2010 | March 2016 |
| NCT01317927 | Completed | Phase 1 | A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies | December 2010 | June 2015 |
| NCT01327313 | Completed | Phase 1 | A Study of EMD525797 in Solid Tumor Patients in Japan | January 2011 | October 2012 |
| NCT01336582 | Completed | Phase 1 | Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer | August 2009 | August 2012 |
| NCT01337765 | Completed | Phase 1 | Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | July 8, 2011 | March 22, 2013 |
| NCT01359696 | Completed | Phase 1 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | July 11, 2011 | May 29, 2014 |
| NCT01363024 | Completed | Phase 1 | Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors | August 2011 | March 2013 |
| NCT01364844 | Completed | Phase 1 | Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors | July 2011 | November 2013 |
| NCT01383473 | Completed | Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients | August 2011 | July 2012 | |
| NCT01388335 | Completed | Phase 1 | A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin | August 2011 | December 2012 |
| NCT01401504 | Completed | Phase 1 | Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors | May 2011 | January 2014 |
| NCT01415258 | Completed | Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre | March 2011 | April 2012 | |
| NCT01425008 | Completed | Phase 1 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma | September 15, 2011 | October 16, 2018 |
| NCT03733587 | Completed | Phase 1 | GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors | October 17, 2018 | May 13, 2020 |
| NCT03758781 | Completed | Phase 1 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | February 13, 2019 | August 11, 2021 |
| NCT00544336 | Completed | Family Quality of Life Among Families With a Member Who is a Cancer Patient | August 2007 | May 2009 | |
| NCT03782467 | Completed | Phase 1 | Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015 | January 30, 2019 | March 3, 2021 |
| NCT03802955 | Completed | Phase 1 | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | December 20, 2018 | November 1, 2021 |
| NCT05093322 | Completed | Phase 1/Phase 2 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | November 30, 2021 | April 25, 2023 |
| NCT03809767 | Completed | Phase 1 | A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas | October 29, 2018 | June 13, 2022 |
| NCT00609297 | Completed | Pain Control in Hospice Patients With Cancer-Related Pain | July 2007 | May 2011 | |
| NCT05046808 | Completed | Phase 1 | Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects | September 23, 2021 | November 22, 2021 |
| NCT03823989 | Completed | Phase 1 | Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients | January 3, 2019 | December 30, 2021 |
| NCT05002868 | Completed | Phase 1 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | October 5, 2021 | April 25, 2024 |
| NCT03834948 | Completed | Phase 1/Phase 2 | AO-176 in Multiple Solid Tumor Malignancies | February 4, 2019 | February 15, 2023 |
| NCT04944888 | Completed | Phase 1 | GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor | July 1, 2021 | November 30, 2023 |
| NCT03861156 | Completed | Phase 2 | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | February 28, 2019 | May 31, 2023 |
| NCT04910633 | Completed | Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach | December 2, 2020 | January 22, 2021 | |
| NCT04886622 | Completed | Phase 1 | A Study of DT2216 in Relapsed/Refractory Malignancies | August 25, 2021 | November 30, 2023 |
| NCT03884556 | Completed | Phase 1 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | April 10, 2019 | September 29, 2023 |
| NCT00697879 | Completed | Phase 1 | Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | February 2008 | November 2011 |
| NCT04862767 | Completed | Phase 1 | TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor | March 9, 2021 | August 21, 2023 |
| NCT03913741 | Completed | Phase 1/Phase 2 | A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies | February 27, 2019 | October 30, 2021 |
| NCT03916094 | Completed | Phase 1 | Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2 | July 31, 2019 | December 27, 2021 |
| NCT03934814 | Completed | Phase 1 | Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | April 16, 2019 | January 10, 2023 |
| NCT00701103 | Completed | Phase 1 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | January 12, 2006 | December 1, 2009 |
| NCT03953235 | Completed | Phase 1/Phase 2 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | July 18, 2019 | March 10, 2023 |
| NCT03961100 | Completed | Phase 1 | A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers. | June 6, 2019 | August 9, 2019 |
| NCT04678921 | Completed | Phase 1 | Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | December 17, 2020 | November 21, 2022 |
| NCT03980041 | Completed | Phase 2 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | September 25, 2019 | November 15, 2022 |
| NCT03987685 | Completed | Phase 1 | Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies | July 19, 2018 | January 9, 2021 |
| NCT03989115 | Completed | Phase 1/Phase 2 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC | July 2, 2019 | February 8, 2022 |
| NCT03990454 | Completed | Phase 1 | Safety Study of SLC-391 in Subjects With Solid Tumors | September 17, 2019 | June 30, 2023 |
| NCT00704366 | Completed | Phase 1 | AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours | June 2008 | May 2011 |
| NCT03994211 | Completed | Phase 1 | Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | May 29, 2019 | August 6, 2021 |
| NCT04601402 | Completed | Phase 1 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | October 26, 2020 | January 11, 2023 |
| NCT04013048 | Completed | Phase 1 | Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor | July 8, 2019 | December 24, 2019 |
| NCT04584515 | Completed | Phase 1 | IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers | November 2, 2020 | May 27, 2021 |
| NCT00717704 | Completed | Phase 1 | Solid Tumors Using Ixabepilone and Dasatinib | July 2008 | May 2011 |
| NCT00718380 | Completed | Phase 1 | A Phase 1 Study of ABT-869 in Subjects With Solid Tumors | September 2008 | June 2012 |
| NCT04035473 | Completed | Phase 1 | A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel | August 1, 2015 | March 27, 2019 |
| NCT04046016 | Completed | Early Phase 1 | A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor | July 3, 2018 | December 24, 2018 |
| NCT04047589 | Completed | Assessing Exercise Behavior and Preferences Among Patients and Oncologists | April 8, 2019 | February 28, 2020 | |
| NCT04057729 | Completed | Phase 1 | IMP4297 Food Effect Trial in Healthy Volunteers | July 22, 2019 | September 27, 2019 |
| NCT04059588 | Completed | Phase 1 | A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin | January 16, 2020 | March 13, 2023 |
| NCT00721669 | Completed | Phase 1 | A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors | June 2008 | December 2012 |
| NCT04079283 | Completed | Radiomics of Immunotherapeutics Response Evaluation and Prediction | January 1, 2017 | February 25, 2020 | |
| NCT04557306 | Completed | Phase 1 | Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer | September 21, 2020 | October 26, 2021 |
| NCT00215501 | Completed | Phase 1 | Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | November 2001 | September 2008 |
| NCT00737555 | Completed | Phase 1 | A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours | August 2006 | March 2008 |
| NCT04552418 | Completed | Early Phase 1 | Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors | June 2, 2021 | January 24, 2023 |
| NCT04537715 | Completed | Phase 1 | Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | April 23, 2020 | April 3, 2023 |
| NCT05230290 | Completed | Phase 1 | Clinical Study of KD6001 in Advanced Solid Tumours | September 10, 2020 | July 26, 2022 |
| NCT00467779 | Completed | Phase 1 | Study of Cobimetinib in Participants With Solid Tumors | May 2007 | April 2014 |
| NCT03536728 | Completed | Phase 1 | Oral AMXT 1501 Dicaprate in Combination With DFMO | June 12, 2018 | April 21, 2023 |
| NCT05190263 | Completed | Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma | October 25, 2021 | February 6, 2022 | |
| NCT05173792 | Completed | Phase 1 | Study of AK119 in Subjects With Advanced Solid Tumors | December 22, 2021 | May 22, 2023 |
| NCT03601611 | Completed | N/A | Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms | January 1, 2019 | January 28, 2020 |
| NCT03602079 | Completed | Phase 1/Phase 2 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | July 16, 2018 | January 12, 2022 |
| NCT03619616 | Completed | Phase 1 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults | July 16, 2018 | October 22, 2019 |
| NCT03636750 | Completed | Phase 1 | A Study of Injection HB002.1T in Subjects With Solid Tumor | June 28, 2018 | March 21, 2020 |
| NCT03641547 | Completed | Phase 1 | M6620 Plus Standard Treatment in Oesophageal and Other Cancer | December 4, 2018 | April 4, 2022 |
| NCT03642834 | Completed | Phase 1 | Study of ICP-105 in Solid Tumors Patients | September 21, 2018 | March 1, 2021 |
| NCT03644056 | Completed | Phase 1 | Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors | March 22, 2018 | May 14, 2020 |
| NCT00470405 | Completed | Phase 1 | Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma | May 2004 | November 2007 |
| NCT03654716 | Completed | Phase 1 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | November 1, 2018 | July 17, 2023 |
| NCT00483457 | Completed | Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients | February 2006 | November 2008 | |
| NCT05134636 | Completed | N/A | Text-based Intervention to Minimize the Time Burden of Routine Cancer Care | December 6, 2021 | December 12, 2022 |
| NCT05126927 | Completed | Early Phase 1 | A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors | November 2, 2021 | August 1, 2022 |
| NCT03707808 | Completed | Phase 1 | Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab | January 29, 2018 | December 24, 2020 |
| NCT05119998 | Completed | Phase 1 | A Phase I Study of IBI325 in Patients With Advanced Solid Tumor | February 8, 2022 | August 8, 2023 |
| NCT03712423 | Completed | Phase 1 | PET Study With [89Zr]-Df-CriPec® Docetaxel | April 1, 2018 | May 8, 2020 |
| NCT03718091 | Completed | Phase 2 | M6620 (VX-970) in Selected Solid Tumors | January 8, 2019 | July 8, 2020 |
| NCT03229200 | Enrolling by invitation | Phase 4 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | May 22, 2017 | July 2, 2027 |
| NCT05741242 | Enrolling by invitation | Phase 1/Phase 2 | Basket Trial of Neoantigen Synthetic Long Peptide Vaccines in Patients With Advanced Malignancy | November 30, 2022 | January 2027 |
| NCT04260269 | Enrolling by invitation | Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study | June 1, 2018 | December 2025 | |
| NCT04644107 | No longer available | Expanded Access for Marizomib | |||
| NCT05322512 | Not yet recruiting | N/A | Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors | May 1, 2024 | December 2025 |
| NCT05361954 | Not yet recruiting | Phase 1 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | August 2023 | February 2027 |
| NCT05369312 | Not yet recruiting | Phase 1 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | June 2022 | May 1, 2025 |
| NCT05381038 | Not yet recruiting | Phase 1/Phase 2 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | June 2022 | April 4, 2027 |
| NCT06349837 | Not yet recruiting | Phase 1 | Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors | April 15, 2024 | March 31, 2026 |
| NCT06041035 | Not yet recruiting | Phase 1/Phase 2 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | October 2023 | October 2025 |
| NCT05455866 | Not yet recruiting | Central Venous Catheter-related Complications in Patients Under Anticancer Treatment | July 11, 2022 | January 2023 | |
| NCT04300088 | Not yet recruiting | A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy | March 10, 2020 | September 10, 2025 | |
| NCT06429891 | Not yet recruiting | N/A | Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization | May 2024 | December 2026 |
| NCT05745454 | Not yet recruiting | N/A | A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors | February 2023 | December 2025 |
| NCT05775666 | Not yet recruiting | Phase 1 | UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors | March 2023 | January 2025 |
| NCT05512780 | Not yet recruiting | Phase 2 | Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer | September 10, 2022 | August 10, 2024 |
| NCT05821595 | Not yet recruiting | Phase 1 | JYB1907 in Subjects With Advanced Solid Tumors | July 31, 2023 | October 31, 2024 |
| NCT05831033 | Not yet recruiting | Early Phase 1 | Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors | May 15, 2023 | June 15, 2026 |
| NCT06112041 | Not yet recruiting | Phase 2 | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) | October 25, 2023 | October 30, 2026 |
| NCT05843305 | Not yet recruiting | Phase 1 | A Study of BPI-452080 in Subjects With Solid Tumors | April 28, 2023 | October 31, 2025 |
| NCT06337630 | Not yet recruiting | Phase 1 | A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors | June 15, 2024 | February 15, 2029 |
| NCT05522491 | Not yet recruiting | Phase 2 | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer | September 1, 2022 | September 1, 2024 |
| NCT06336148 | Not yet recruiting | Phase 1 | A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors | April 2024 | July 2026 |
| NCT05940116 | Not yet recruiting | Phase 1 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | July 20, 2023 | July 30, 2027 |
| NCT06134960 | Not yet recruiting | Phase 1 | NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor | November 16, 2023 | November 15, 2026 |
| NCT06150885 | Not yet recruiting | Phase 1/Phase 2 | A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors | April 30, 2024 | September 30, 2027 |
| NCT06212076 | Not yet recruiting | Phase 1/Phase 2 | Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients | February 20, 2024 | August 15, 2024 |
| NCT06297525 | Not yet recruiting | Phase 1 | Study of STP938 in Advanced Solid Tumours | September 2024 | May 2027 |
| NCT06332430 | Not yet recruiting | Phase 1 | Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas | May 30, 2024 | May 30, 2026 |
| NCT05954091 | Not yet recruiting | Phase 1 | OH2 Administered by Intratumoral Injection | September 1, 2023 | January 1, 2026 |
| NCT06416436 | Not yet recruiting | Phase 1 | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | May 23, 2024 | July 1, 2027 |
| NCT06401356 | Not yet recruiting | Phase 3 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | June 1, 2024 | June 30, 2024 |
| NCT05115500 | Not yet recruiting | Phase 2 | ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) | November 1, 2021 | April 30, 2025 |
| NCT05528406 | Not yet recruiting | Phase 2 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation | October 20, 2022 | June 1, 2025 |
| NCT06375187 | Not yet recruiting | Phase 1 | Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors | May 1, 2024 | May 1, 2027 |
| NCT05971576 | Not yet recruiting | Early Phase 1 | A Clinical Study on TILs for the Treatment of Advanced Solid Tumors | August 2023 | August 2026 |
| NCT05095441 | Not yet recruiting | Phase 1 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | March 15, 2023 | April 30, 2026 |
| NCT05539183 | Not yet recruiting | N/A | Collection of Pleural Effusion Fluid | October 1, 2022 | December 31, 2025 |
| NCT05638828 | Not yet recruiting | Early Phase 1 | A Study of RD14-01 in Patients With Advanced Solid Tumors | December 1, 2022 | December 1, 2024 |
| NCT06245018 | Not yet recruiting | N/A | A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor | February 1, 2024 | March 1, 2030 |
| NCT06190886 | Not yet recruiting | Phase 1 | A First-in-human (FIH), Multicenter, Open-Label, Phase I Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors | April 27, 2024 | July 24, 2026 |
| NCT05971589 | Not yet recruiting | Early Phase 1 | A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors | August 2023 | August 2026 |
| NCT06215846 | Not yet recruiting | Phase 1 | A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors | January 22, 2024 | April 2, 2026 |
| NCT05982522 | Not yet recruiting | Phase 1/Phase 2 | IN10018 Combination Therapy in Previously-treated Solid Tumors | August 2023 | July 2026 |
| NCT05284968 | Not yet recruiting | Early Phase 1 | RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors | April 1, 2022 | April 1, 2025 |
| NCT06010342 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | May 2024 | December 2025 |
| NCT05649618 | Not yet recruiting | Early Phase 1 | TIL Cells for the Treatment of the Advanced Solid Tumors Patients | December 5, 2022 | March 2026 |
| NCT06198426 | Not yet recruiting | Phase 1/Phase 2 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | May 1, 2024 | May 1, 2026 |
| NCT06443710 | Not yet recruiting | Phase 1 | Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers | May 30, 2024 | December 31, 2024 |
| NCT06465017 | Recruiting | N/A | ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer | June 12, 2024 | June 30, 2026 |
| NCT00736749 | Recruiting | Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | July 17, 2008 | ||
| NCT02332668 | Recruiting | Phase 1/Phase 2 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | March 18, 2015 | October 25, 2027 |
| NCT02446431 | Recruiting | Early Phase 1 | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | July 2014 | July 2029 |
| NCT02534649 | Recruiting | N/A | Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials | December 2015 | December 2029 |
| NCT02806388 | Recruiting | Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project | October 2011 | December 31, 2025 | |
| NCT03016806 | Recruiting | Phase 1 | Umbilical Cord Blood Transplantation From Unrelated Donors | June 2015 | June 2026 |
| NCT03129139 | Recruiting | Phase 1 | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors | October 10, 2017 | December 1, 2024 |
| NCT03340506 | Recruiting | Phase 4 | Dabrafenib and/or Trametinib Rollover Study | December 28, 2017 | December 21, 2027 |
| NCT03517917 | Recruiting | Prospective Tissue Collection Research Protocol | February 8, 2018 | August 31, 2025 | |
| NCT03611595 | Recruiting | Phase 1 | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | August 28, 2018 | August 2024 |
| NCT03647163 | Recruiting | Phase 1/Phase 2 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | April 9, 2019 | December 1, 2024 |
| NCT03658785 | Recruiting | Phase 1/Phase 2 | Immunotherapy for the Treatment of Advanced Solid Tumor | April 28, 2020 | December 31, 2025 |
| NCT03667170 | Recruiting | Phase 2 | KN035 for dMMR/MSI-H Advanced Solid Tumors | August 22, 2018 | December 15, 2025 |
| NCT03739827 | Recruiting | Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors | January 28, 2019 | March 31, 2028 | |
| NCT03740256 | Recruiting | Phase 1 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | December 14, 2020 | December 30, 2038 |
| NCT03758664 | Recruiting | Phase 1/Phase 2 | Clinical Study of ICP-192 in Solid Tumors Patients | December 19, 2018 | December 31, 2024 |
| NCT03781219 | Recruiting | Phase 1 | A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation | July 1, 2018 | December 1, 2023 |
| NCT03810339 | Recruiting | Phase 2 | Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | January 15, 2019 | January 15, 2024 |
| NCT03829254 | Recruiting | Phase 1/Phase 2 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | June 17, 2019 | June 2024 |
| NCT03838042 | Recruiting | Phase 1/Phase 2 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | May 26, 2020 | June 30, 2027 |
| NCT03866525 | Recruiting | Phase 1/Phase 2 | OH2 Oncolytic Viral Therapy in Solid Tumors | April 2, 2019 | August 30, 2024 |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT03891706 | Recruiting | Phase 1 | Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors | January 8, 2019 | December 31, 2024 |
| NCT03943004 | Recruiting | Phase 1 | Trial of DFP-14927 in Advanced Solid Tumors | September 30, 2019 | December 1, 2024 |
| NCT03991832 | Recruiting | Phase 2 | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors | December 31, 2019 | March 31, 2025 |
| NCT04015609 | Recruiting | N/A | Psychotherapy Intervention for Latinos With Advanced Cancer | April 20, 2015 | August 31, 2025 |
| NCT04021277 | Recruiting | Phase 1 | PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin | September 17, 2019 | June 2024 |
| NCT04064359 | Recruiting | Phase 1 | Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | July 25, 2019 | December 31, 2027 |
| NCT04084067 | Recruiting | Phase 1 | Indocyanine Green (ICG) Guided Tumor Resection | February 7, 2020 | December 31, 2025 |
| NCT04096638 | Recruiting | Phase 1 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | September 23, 2019 | March 2027 |
| NCT04107311 | Recruiting | Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients | September 5, 2019 | March 5, 2025 | |
| NCT04158336 | Recruiting | Phase 1 | A Study of ZN-c3 in Participants With Solid Tumors | November 1, 2019 | August 2023 |
| NCT04165772 | Recruiting | Phase 2 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | December 11, 2019 | November 30, 2026 |
| NCT04175847 | Recruiting | Phase 1/Phase 2 | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | April 14, 2020 | September 2025 |
| NCT04185831 | Recruiting | Phase 2 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial | October 20, 2020 | October 2024 |
| NCT04196257 | Recruiting | Phase 1 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | August 19, 2022 | October 2024 |
| NCT04198766 | Recruiting | Phase 1 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | December 10, 2019 | May 15, 2026 |
| NCT04214717 | Recruiting | N/A | Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor | December 31, 2019 | December 31, 2024 |
| NCT04214730 | Recruiting | N/A | Study of NK Combined With Chemotherapy for Advanced Solid Tumor | December 31, 2019 | December 2023 |
| NCT04243720 | Recruiting | Immune Resistance Interrogation Study | August 26, 2020 | February 2025 | |
| NCT04249843 | Recruiting | Phase 1 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | February 17, 2020 | June 30, 2025 |
| NCT04300556 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | August 6, 2020 | March 31, 2025 |
| NCT04305249 | Recruiting | Phase 1 | Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies | August 15, 2020 | June 30, 2024 |
| NCT04319757 | Recruiting | Phase 1 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | May 19, 2020 | June 2024 |
| NCT05212987 | Recruiting | Phase 1 | Study of FCN-098 in Patients With Advanced Solid Tumor | December 31, 2021 | October 12, 2024 |
| NCT05217693 | Recruiting | Phase 1 | A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors | June 1, 2022 | December 2025 |
| NCT05238792 | Recruiting | Phase 1 | Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors | November 17, 2021 | October 2027 |
| NCT05244551 | Recruiting | Phase 1 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | June 30, 2022 | April 30, 2025 |
| NCT05245136 | Recruiting | Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool. | March 29, 2021 | April 2025 | |
| NCT05245500 | Recruiting | Phase 1/Phase 2 | Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | June 2, 2022 | April 30, 2026 |
| NCT05262530 | Recruiting | Phase 1/Phase 2 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | March 28, 2022 | April 2026 |
| NCT05266612 | Recruiting | Phase 1 | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | November 9, 2022 | December 31, 2025 |
| NCT05269316 | Recruiting | Phase 1 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | February 11, 2022 | July 31, 2025 |
| NCT05278364 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | April 23, 2021 | February 10, 2025 |
| NCT05301101 | Recruiting | N/A | High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis | June 13, 2022 | July 2027 |
| NCT05306509 | Recruiting | N/A | Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology | August 1, 2022 | December 31, 2024 |
| NCT05346484 | Recruiting | Phase 1 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | May 17, 2022 | January 2025 |
| NCT05357651 | Recruiting | Phase 1 | A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） | August 12, 2022 | March 11, 2025 |
| NCT05359354 | Recruiting | N/A | Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors | September 1, 2022 | December 2025 |
| NCT05373147 | Recruiting | Early Phase 1 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | October 30, 2020 | August 2023 |
| NCT05375084 | Recruiting | Phase 1 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | October 20, 2022 | January 2025 |
| NCT05379946 | Recruiting | Phase 1/Phase 2 | Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | October 12, 2022 | December 30, 2024 |
| NCT05380986 | Recruiting | N/A | Camrelizumab Combined With Apatinib Mesylate | May 20, 2022 | May 1, 2025 |
| NCT05382377 | Recruiting | Early Phase 1 | NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors | May 17, 2022 | May 17, 2026 |
| NCT05382559 | Recruiting | Phase 1 | A Study of ASP3082 in Adults With Previously Treated Solid Tumors | June 8, 2022 | October 31, 2026 |
| NCT05383482 | Recruiting | Phase 1/Phase 2 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | June 30, 2022 | December 31, 2025 |
| NCT05385692 | Recruiting | Phase 1 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors | June 1, 2022 | June 2024 |
| NCT05390827 | Recruiting | Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol | May 19, 2022 | May 2025 | |
| NCT05403177 | Recruiting | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) | June 23, 2022 | October 2026 | |
| NCT05416710 | Recruiting | Universal Germline Testing in the Community | June 1, 2022 | June 1, 2025 | |
| NCT05423262 | Recruiting | Phase 1 | A Study of TRK-950 in Patients With Advanced Solid Tumors | July 6, 2022 | February 2025 |
| NCT05430360 | Recruiting | Phase 1 | Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors | January 4, 2022 | May 2025 |
| NCT05436093 | Recruiting | N/A | CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors | June 23, 2022 | December 2024 |
| NCT05437315 | Recruiting | Phase 1/Phase 2 | GD2/PSMA Bi-specific CAR-T Cell Therapy | June 30, 2022 | June 30, 2026 |
| NCT05470348 | Recruiting | Phase 1 | A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | August 11, 2022 | August 2024 |
| NCT05480904 | Recruiting | Characterizing Sleep Among Long-term Survivors of Childhood Cancer | April 17, 2023 | December 2025 | |
| NCT05485974 | Recruiting | Phase 1 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | August 1, 2022 | August 2025 |
| NCT05490264 | Recruiting | Early Phase 1 | [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors | October 18, 2022 | July 30, 2024 |
| NCT05497453 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene | August 19, 2022 | December 2028 |
| NCT05500508 | Recruiting | Phase 1/Phase 2 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | November 29, 2022 | September 30, 2024 |
| NCT05507736 | Recruiting | N/A | Feasibility and Safety of Acupuncture in the Prevention of Late Irinotecan-related Diarrhea in Pediatric Patients | January 15, 2022 | December 31, 2022 |
| NCT05512208 | Recruiting | Phase 2 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | February 6, 2023 | December 2029 |
| NCT05522868 | Recruiting | Phase 1 | SB17170 Phase 1 Clinical Trial in Solid Tumors | October 17, 2022 | June 30, 2025 |
| NCT05525767 | Recruiting | Phase 4 | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer | March 31, 2022 | December 31, 2025 |
| NCT05525858 | Recruiting | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | September 28, 2022 | September 2025 | |
| NCT05528055 | Recruiting | Phase 1 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | May 18, 2022 | October 2027 |
| NCT05534178 | Recruiting | Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients | February 15, 2020 | March 15, 2024 | |
| NCT05544240 | Recruiting | Phase 1 | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors | February 1, 2023 | December 31, 2024 |
| NCT05544552 | Recruiting | Phase 1/Phase 2 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | November 22, 2022 | June 2027 |
| NCT05557045 | Recruiting | Phase 1 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | October 10, 2022 | April 1, 2028 |
| NCT05566574 | Recruiting | Phase 1/Phase 2 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | September 30, 2022 | September 30, 2025 |
| NCT05576961 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | September 15, 2022 | December 31, 2024 |
| NCT05578092 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | November 4, 2022 | July 30, 2026 |
| NCT05580796 | Recruiting | Early Phase 1 | KSH01-R02-101 Solid Tumors | October 11, 2022 | October 11, 2027 |
| NCT05580991 | Recruiting | Phase 1 | Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors | September 9, 2022 | December 31, 2024 |
| NCT05583201 | Recruiting | Early Phase 1 | NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | October 13, 2022 | June 1, 2026 |
| NCT05584670 | Recruiting | Phase 1/Phase 2 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | November 29, 2022 | September 27, 2028 |
| NCT05585684 | Recruiting | Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection | January 27, 2023 | September 2025 | |
| NCT05626764 | Recruiting | QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management | January 27, 2020 | December 2024 | |
| NCT05627063 | Recruiting | Phase 1 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | June 26, 2023 | June 30, 2025 |
| NCT05642780 | Recruiting | Phase 2 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | January 17, 2023 | November 22, 2025 |
| NCT05645523 | Recruiting | Early Phase 1 | Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors | October 24, 2023 | December 2025 |
| NCT05653882 | Recruiting | Phase 1 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | January 4, 2023 | May 2027 |
| NCT05661201 | Recruiting | Phase 1 | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | April 12, 2023 | January 2026 |
| NCT05672459 | Recruiting | Phase 1/Phase 2 | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | June 21, 2023 | December 29, 2029 |
| NCT05678010 | Recruiting | Phase 1 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | May 17, 2023 | May 17, 2028 |
| NCT05691608 | Recruiting | N/A | MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 | September 9, 2022 | September 9, 2030 |
| NCT05701306 | Recruiting | Phase 1 | APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors | February 28, 2023 | December 31, 2027 |
| NCT05704985 | Recruiting | Phase 1 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | April 3, 2023 | February 2025 |
| NCT05707325 | Recruiting | Phase 1 | Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies | October 31, 2022 | July 31, 2024 |
| NCT05707676 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001） | November 30, 2022 | September 2026 |
| NCT05708950 | Recruiting | Phase 1/Phase 2 | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | March 3, 2023 | December 31, 2024 |
| NCT05717348 | Recruiting | Phase 1 | A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours | February 21, 2023 | September 30, 2025 |
| NCT05718557 | Recruiting | Phase 1 | Study of PYX-106 in Solid Tumors | May 23, 2023 | August 2025 |
| NCT05720117 | Recruiting | Phase 1 | Study of PYX-201 in Solid Tumors | March 14, 2023 | July 2026 |
| NCT05722886 | Recruiting | Phase 2/Phase 3 | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol | March 1, 2023 | October 2029 |
| NCT05724732 | Recruiting | Early Phase 1 | Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors | February 1, 2023 | May 1, 2025 |
| NCT05729399 | Recruiting | Early Phase 1 | Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors | September 14, 2022 | May 1, 2025 |
| NCT05735080 | Recruiting | Phase 1/Phase 2 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | March 28, 2023 | June 2026 |
| NCT05735366 | Recruiting | Phase 1 | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | April 18, 2023 | December 31, 2028 |
| NCT05736731 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | April 28, 2023 | December 2028 |
| NCT05737706 | Recruiting | Phase 1/Phase 2 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | March 20, 2023 | August 30, 2026 |
| NCT05748938 | Recruiting | Phase 1/Phase 2 | A Study of RD14-01 in Patients With Advanced Solid Tumors | February 8, 2023 | February 8, 2025 |
| NCT05749432 | Recruiting | Phase 1 | A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors | March 20, 2023 | July 31, 2025 |
| NCT05767684 | Recruiting | Phase 1 | Neoantigen Derived DCs as Cancer Treatment | June 1, 2023 | March 30, 2026 |
| NCT05768178 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | March 1, 2023 | October 2029 |
| NCT05770037 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers | December 18, 2023 | October 2029 |
| NCT05770544 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | June 2024 | October 2029 |
| NCT05784688 | Recruiting | Phase 1/Phase 2 | Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | March 10, 2023 | December 2028 |
| NCT05785039 | Recruiting | Phase 2 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors | April 20, 2023 | April 2025 |
| NCT05786716 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations | March 7, 2023 | October 2029 |
| NCT05786924 | Recruiting | Phase 1 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | April 18, 2023 | December 2026 |
| NCT05798026 | Recruiting | Phase 1 | A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy | August 8, 2023 | December 31, 2025 |
| NCT05798533 | Recruiting | Phase 1 | Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | January 10, 2023 | September 2024 |
| NCT05798546 | Recruiting | Phase 1 | Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | September 28, 2022 | September 2024 |
| NCT05803018 | Recruiting | Phase 1/Phase 2 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies | June 25, 2023 | June 2025 |
| NCT05807035 | Recruiting | Phase 1 | Autologous Tumour Vaccine Trial | February 10, 2023 | February 10, 2028 |
| NCT05826600 | Recruiting | Phase 1/Phase 2 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | March 30, 2023 | April 2026 |
| NCT05828238 | Recruiting | Early Phase 1 | Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy | January 2023 | January 2024 |
| NCT05828459 | Recruiting | Phase 1 | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | July 10, 2023 | July 2027 |
| NCT05833984 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | May 17, 2022 | November 20, 2024 |
| NCT05840224 | Recruiting | Phase 1 | Study of GS-4528 in Adults With Solid Tumors | May 11, 2023 | December 2025 |
| NCT05858424 | Recruiting | N/A | Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer | November 29, 2022 | September 2025 |
| NCT05859074 | Recruiting | Phase 1 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | May 4, 2023 | May 4, 2028 |
| NCT05868226 | Recruiting | Phase 1 | PRE-I-SPY Phase I/Ib Oncology Platform Program | December 22, 2022 | December 30, 2027 |
| NCT05869240 | Recruiting | Phase 1/Phase 2 | BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors | May 16, 2023 | September 1, 2025 |
| NCT05895370 | Recruiting | Phase 1 | HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors | April 13, 2023 | April 13, 2025 |
| NCT05907980 | Recruiting | Phase 1 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | May 24, 2023 | December 31, 2026 |
| NCT05909436 | Recruiting | Phase 1/Phase 2 | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | October 31, 2022 | December 2026 |
| NCT05919264 | Recruiting | Phase 1/Phase 2 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | May 19, 2023 | August 31, 2027 |
| NCT05923008 | Recruiting | Phase 1/Phase 2 | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | November 14, 2023 | October 31, 2026 |
| NCT05934539 | Recruiting | Phase 1/Phase 2 | ALG.APV-527 First-in-human Study | December 23, 2022 | December 1, 2025 |
| NCT05935098 | Recruiting | Phase 1 | A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors | August 21, 2023 | February 2025 |
| NCT05938296 | Recruiting | Phase 1 | oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection | December 19, 2023 | January 1, 2026 |
| NCT05940181 | Recruiting | N/A | A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors | March 1, 2023 | December 2025 |
| NCT05940896 | Recruiting | Phase 1 | RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression | June 29, 2023 | February 28, 2027 |
| NCT05941936 | Recruiting | Early Phase 1 | A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors | May 19, 2023 | February 2026 |
| NCT05943041 | Recruiting | Phase 1 | Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer | April 28, 2023 | December 31, 2023 |
| NCT05965856 | Recruiting | Phase 2 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | December 11, 2023 | December 2025 |
| NCT05981703 | Recruiting | Phase 1 | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | September 7, 2023 | February 2027 |
| NCT05985161 | Recruiting | Phase 2 | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | August 1, 2023 | August 1, 2029 |
| NCT05989724 | Recruiting | Phase 1 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | September 19, 2023 | March 2026 |
| NCT05989997 | Recruiting | Phase 1 | Phase I Clinical Trial of 68Ga-NOTA-SNA002 | November 1, 2023 | June 30, 2024 |
| NCT05991349 | Recruiting | Phase 1/Phase 2 | A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | March 12, 2024 | May 31, 2025 |
| NCT06004713 | Recruiting | Registry Study in MSI/dMMR Solid Tumors | October 7, 2023 | February 2026 | |
| NCT06005974 | Recruiting | Phase 2 | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | January 15, 2024 | January 2027 |
| NCT06008483 | Recruiting | Phase 1 | A Dose Finding Study to Treat Bone Tumor(s) | April 5, 2022 | November 1, 2024 |
| NCT06009835 | Recruiting | DOTr/DOTa Algorithm Guidance for Refractory Solid Tumors | August 7, 2022 | September 1, 2024 | |
| NCT06014502 | Recruiting | Phase 1 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | September 7, 2023 | December 2027 |
| NCT06015269 | Recruiting | Phase 1 | Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery | August 2023 | July 2025 |
| NCT06016062 | Recruiting | Phase 1 | A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | September 14, 2023 | December 31, 2025 |
| NCT06022276 | Recruiting | N/A | Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors | December 1, 2022 | December 31, 2024 |
| NCT06022289 | Recruiting | Phase 2 | Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | May 1, 2023 | May 31, 2025 |
| NCT06028724 | Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) | May 26, 2023 | May 31, 2030 | |
| NCT06036836 | Recruiting | Phase 2 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | September 29, 2023 | March 9, 2027 |
| NCT06046742 | Recruiting | Phase 1 | A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors | May 10, 2024 | December 20, 2026 |
| NCT06065592 | Recruiting | Phase 1 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms | February 1, 2019 | December 2024 |
| NCT06075849 | Recruiting | Phase 1 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | October 25, 2023 | January 2025 |
| NCT06086522 | Recruiting | Phase 1 | Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors | November 1, 2023 | December 2026 |
| NCT06094426 | Recruiting | Early Phase 1 | Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors | February 26, 2023 | February 26, 2026 |
| NCT06101082 | Recruiting | Phase 1 | A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors | January 16, 2024 | October 19, 2026 |
| NCT06102837 | Recruiting | Tumor Vaccines for Solid Tumors | October 2023 | October 2027 | |
| NCT06104488 | Recruiting | Phase 1 | A Study of Avutometinib for People With Solid Tumor Cancers | October 20, 2023 | October 20, 2029 |
| NCT06105021 | Recruiting | Phase 1/Phase 2 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | March 6, 2024 | December 2029 |
| NCT06106360 | Recruiting | A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy | October 26, 2023 | November 26, 2025 | |
| NCT06117540 | Recruiting | Phase 2 | A Study of WX390 in Patients With Advanced Solid Tumors | May 11, 2021 | June 2024 |
| NCT06117566 | Recruiting | Phase 1/Phase 2 | A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors | November 18, 2022 | March 2025 |
| NCT06132828 | Recruiting | Phase 1 | Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors | November 27, 2023 | July 30, 2026 |
| NCT06145802 | Recruiting | N/A | Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors) | March 9, 2023 | March 9, 2026 |
| NCT06160752 | Recruiting | Phase 1 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | November 22, 2023 | September 2027 |
| NCT06166836 | Recruiting | Phase 1/Phase 2 | a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors | October 12, 2022 | December 31, 2026 |
| NCT06166888 | Recruiting | Phase 1 | A Study of AK131 in Patients With Advanced Solid Tumors | January 10, 2024 | December 2028 |
| NCT06171178 | Recruiting | Phase 1 | A Study of ASP1012 in Adults With Solid Tumors | February 28, 2024 | June 30, 2029 |
| NCT06171750 | Recruiting | Phase 1 | Phase I Study of ANK-101 in Advanced Solid Tumors | January 19, 2024 | January 2026 |
| NCT06184035 | Recruiting | Phase 1/Phase 2 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer | November 30, 2023 | December 31, 2027 |
| NCT06188468 | Recruiting | N/A | ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors | October 1, 2023 | October 1, 2025 |
| NCT06209385 | Recruiting | Phase 1 | A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors | August 11, 2023 | January 2028 |
| NCT06210815 | Recruiting | Phase 1 | A Study of HLX42 in Advanced/Metastatic Solid Tumors | March 14, 2024 | July 1, 2026 |
| NCT06220318 | Recruiting | Phase 1/Phase 2 | Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors | July 19, 2023 | August 30, 2026 |
| NCT06234098 | Recruiting | Phase 1/Phase 2 | Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | February 13, 2024 | January 2027 |
| NCT06234423 | Recruiting | Phase 1 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | February 9, 2024 | August 31, 2027 |
| NCT06237413 | Recruiting | Phase 1/Phase 2 | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | August 10, 2023 | February 2026 |
| NCT06239298 | Recruiting | Phase 1/Phase 2 | A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor | May 10, 2024 | May 2026 |
| NCT06239623 | Recruiting | Phase 1 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | April 2, 2022 | December 30, 2024 |
| NCT06241898 | Recruiting | Phase 1 | A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors | October 1, 2023 | December 30, 2026 |
| NCT06245330 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | July 7, 2022 | August 31, 2027 |
| NCT06248697 | Recruiting | Early Phase 1 | Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors | January 1, 2023 | December 31, 2026 |
| NCT06249256 | Recruiting | Early Phase 1 | An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells | June 1, 2023 | December 31, 2026 |
| NCT06258330 | Recruiting | Phase 1 | Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors | June 22, 2022 | June 15, 2024 |
| NCT06259552 | Recruiting | Phase 1 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors | March 20, 2024 | September 2027 |
| NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
| NCT06290388 | Recruiting | Phase 1/Phase 2 | Study of 23ME-01473 in Patients With Advanced Solid Malignancies | March 7, 2024 | June 30, 2026 |
| NCT06299761 | Recruiting | Phase 1 | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications | March 28, 2024 | February 2027 |
| NCT06305247 | Recruiting | Phase 1/Phase 2 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | April 3, 2024 | March 20, 2028 |
| NCT06307249 | Recruiting | Phase 1 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA | February 15, 2023 | December 2027 |
| NCT06308263 | Recruiting | Phase 1 | M1774 Human Mass Balance Study (DDRIVER Solid Tumors 303) | March 25, 2024 | November 26, 2025 |
| NCT06310655 | Recruiting | N/A | Online Proton Adaptive Radiotherapy | May 2, 2024 | August 31, 2025 |
| NCT06326242 | Recruiting | What Unmet Need for the Patients?A Focus on the Social Determinants of Health in Phase 1 Clinical Trials | March 27, 2023 | December 31, 2024 | |
| NCT06327997 | Recruiting | Early Phase 1 | An Exploratory Study by Fast CAR T Cells | March 7, 2024 | December 31, 2027 |
| NCT06339541 | Recruiting | The ACC Preclinical Research Platform for Precision Oncology | June 5, 2023 | December 1, 2024 | |
| NCT06342336 | Recruiting | Phase 1 | HS-IT101 Injection in the Treatment of Advanced Solid Tumors | January 18, 2024 | March 31, 2028 |
| NCT06364696 | Recruiting | Phase 1 | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | April 16, 2024 | April 30, 2027 |
| NCT06368921 | Recruiting | Phase 1 | A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors | April 2024 | December 2025 |
| NCT06383598 | Recruiting | N/A | PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors | May 9, 2024 | December 2026 |
| NCT06384807 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors | April 22, 2024 | February 2028 |
| NCT06394622 | Recruiting | Phase 1 | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors | April 11, 2024 | June 28, 2026 |
| NCT06403735 | Recruiting | Phase 1 | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors | April 25, 2024 | April 30, 2027 |
| NCT06410092 | Recruiting | Phase 1 | Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 | June 5, 2023 | March 2027 |
| NCT06425926 | Recruiting | Phase 1/Phase 2 | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | May 9, 2024 | November 2026 |
| NCT06443307 | Recruiting | Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan | July 15, 2024 | August 1, 2026 | |
| NCT06452160 | Recruiting | Phase 1 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | June 2024 | December 2027 |
| NCT04370587 | Recruiting | Phase 1/Phase 2 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | September 17, 2020 | October 31, 2025 |
| NCT04381806 | Recruiting | Phase 1 | Phase I Study in Advanced Malignancies With 5-ALA | July 30, 2020 | February 1, 2027 |
| NCT04386967 | Recruiting | Phase 1/Phase 2 | OH2 Injection in Solid Tumors | November 22, 2018 | December 13, 2024 |
| NCT04407741 | Recruiting | Phase 1/Phase 2 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | September 1, 2020 | December 1, 2025 |
| NCT04419532 | Recruiting | Phase 1 | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | October 9, 2020 | December 31, 2024 |
| NCT04452955 | Recruiting | Phase 2 | A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | December 12, 2020 | December 1, 2023 |
| NCT04469530 | Recruiting | Phase 2 | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors | September 16, 2020 | September 2025 |
| NCT04475705 | Recruiting | Phase 4 | Propofol vs Sevo for Paediatric Tumor Surgery | January 11, 2021 | July 2028 |
| NCT04485416 | Recruiting | Phase 1 | Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors | July 16, 2021 | December 2024 |
| NCT04503278 | Recruiting | Phase 1 | A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors | September 16, 2020 | January 2040 |
| NCT04511871 | Recruiting | Phase 1 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | July 9, 2020 | March 29, 2025 |
| NCT04513444 | Recruiting | Phase 2 | Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy | December 7, 2020 | February 2026 |
| NCT04516447 | Recruiting | Phase 1 | A Study of ZN-c3 in Patients With Ovarian Cancer | October 26, 2020 | February 28, 2027 |
| NCT04522284 | Recruiting | Phase 1/Phase 2 | PRECISE CURATE.AI Pilot Clinical Trial | August 20, 2020 | August 1, 2023 |
| NCT04526470 | Recruiting | Phase 1/Phase 2 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | September 1, 2020 | December 2024 |
| NCT04537936 | Recruiting | N/A | Psychotherapy Intervention for Latinos With Adv Cancer | January 1, 2019 | August 31, 2024 |
| NCT04541108 | Recruiting | Early Phase 1 | Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | July 26, 2021 | December 2031 |
| NCT04542863 | Recruiting | N/A | The Molecular Imaging Research of F-18 Labeled DX600 PET Probe | September 11, 2020 | September 2024 |
| NCT04553692 | Recruiting | Phase 1 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers | September 23, 2020 | August 2027 |
| NCT04606472 | Recruiting | Phase 1 | A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | November 10, 2020 | May 2024 |
| NCT04617054 | Recruiting | Phase 2 | Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene | June 1, 2021 | December 31, 2026 |
| NCT04617314 | Recruiting | Phase 1 | A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors | March 10, 2021 | December 31, 2025 |
| NCT04647838 | Recruiting | Phase 2 | Tepotinib in Solid Tumors Harboring MET Alterations | January 16, 2020 | August 31, 2024 |
| NCT04648254 | Recruiting | Phase 1 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor | November 18, 2020 | February 28, 2025 |
| NCT04665388 | Recruiting | LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers | November 30, 2020 | February 28, 2026 | |
| NCT04666688 | Recruiting | Phase 1/Phase 2 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | December 15, 2020 | January 2025 |
| NCT04695327 | Recruiting | Phase 1 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy | January 11, 2021 | March 31, 2025 |
| NCT04706676 | Recruiting | N/A | Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer | January 26, 2021 | September 2026 |
| NCT04706962 | Recruiting | Phase 1 | TH1902 in Patients With Advanced Solid Tumors | March 4, 2021 | December 2024 |
| NCT04710043 | Recruiting | Phase 1 | Dose Escalation Trial of BNT152+153 in Patients With Cancer | June 8, 2021 | September 2025 |
| NCT04720976 | Recruiting | Phase 1/Phase 2 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | March 23, 2021 | February 5, 2024 |
| NCT04776005 | Recruiting | COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies | January 22, 2021 | February 2024 | |
| NCT04787042 | Recruiting | Phase 1/Phase 2 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | August 6, 2021 | January 30, 2025 |
| NCT04794699 | Recruiting | Phase 1 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | April 14, 2021 | March 30, 2027 |
| NCT04794972 | Recruiting | Phase 1 | A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors | April 14, 2021 | June 2024 |
| NCT04796012 | Recruiting | Phase 1/Phase 2 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | April 18, 2023 | January 2025 |
| NCT04891198 | Recruiting | Phase 2 | ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors | August 6, 2021 | April 30, 2028 |
| NCT04900519 | Recruiting | Phase 1 | Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | November 24, 2021 | March 2025 |
| NCT04900818 | Recruiting | Phase 1 | Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors | June 29, 2021 | December 2024 |
| NCT04903873 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | May 31, 2021 | December 2025 |
| NCT04911907 | Recruiting | Phase 2 | Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors | January 22, 2021 | December 30, 2024 |
| NCT04927663 | Recruiting | Phase 1 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | August 10, 2021 | October 31, 2025 |
| NCT04928612 | Recruiting | Phase 1 | A Study of CBP-1018 in Patients With Advanced Solid Tumors | November 4, 2021 | October 2024 |
| NCT04930354 | Recruiting | Phase 1 | ECP-1014 Treatment for Patients With Solid Tumor Cancers | May 2023 | December 2023 |
| NCT04930432 | Recruiting | Phase 1/Phase 2 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | September 24, 2021 | June 30, 2025 |
| NCT04931823 | Recruiting | Phase 1 | Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors | March 24, 2021 | March 1, 2025 |
| NCT04942717 | Recruiting | Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values | June 18, 2021 | June 18, 2026 | |
| NCT04952272 | Recruiting | Phase 1 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | March 1, 2021 | June 30, 2036 |
| NCT04965220 | Recruiting | Phase 1 | HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors | January 5, 2022 | June 30, 2025 |
| NCT04970121 | Recruiting | Phase 2 | Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients With Taxanes-induced Painful Peripheral Neuropathy | August 21, 2021 | January 1, 2025 |
| NCT04970992 | Recruiting | Phase 1 | A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | August 12, 2021 | March 2025 |
| NCT04977167 | Recruiting | Phase 1 | Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma | July 28, 2023 | December 2024 |
| NCT04982926 | Recruiting | Phase 1 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | September 16, 2021 | June 2025 |
| NCT04984668 | Recruiting | Phase 1/Phase 2 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | November 2, 2021 | December 2025 |
| NCT04985604 | Recruiting | Phase 1/Phase 2 | Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors | July 15, 2021 | December 31, 2025 |
| NCT04987112 | Recruiting | Phase 1 | Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors | January 20, 2022 | December 30, 2024 |
| NCT04991506 | Recruiting | Phase 1 | A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | October 15, 2021 | June 30, 2025 |
| NCT05023655 | Recruiting | Phase 2 | Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | January 6, 2022 | January 2026 |
| NCT05025358 | Recruiting | Phase 1 | A Study of LP-118 in Patients With Advanced Tumors | September 14, 2021 | July 30, 2024 |
| NCT05058937 | Recruiting | N/A | A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre | June 1, 2021 | May 2026 |
| NCT05076552 | Recruiting | Phase 1 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer | February 17, 2023 | July 2025 |
| NCT05076760 | Recruiting | Phase 1 | MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer | February 23, 2022 | November 2026 |
| NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
| NCT05088070 | Recruiting | Phase 1 | Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors | July 2, 2020 | December 30, 2024 |
| NCT05097781 | Recruiting | Phase 2 | Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients | March 21, 2021 | September 2024 |
| NCT05100251 | Recruiting | Phase 1 | Clinical Trial of WB100 on Advanced Solid Tumor | October 25, 2021 | October 25, 2023 |
| NCT05103631 | Recruiting | Phase 1 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | June 17, 2021 | December 2039 |
| NCT05119907 | Recruiting | Phase 2 | Study of Sacituzumab Govitecan in Patients With Solid Tumor | October 12, 2021 | December 2025 |
| NCT05128487 | Recruiting | Phase 1/Phase 2 | A Study of NDI 1150-101 in Patients With Solid Tumors | November 5, 2021 | December 2024 |
| NCT05144698 | Recruiting | Phase 1/Phase 2 | RAPA-201 Therapy of Solid Tumors | August 1, 2021 | December 31, 2024 |
| NCT05150405 | Recruiting | Phase 1 | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors | October 19, 2021 | June 1, 2024 |
| NCT05159245 | Recruiting | Phase 2 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | December 10, 2021 | November 25, 2026 |
| NCT05159388 | Recruiting | Phase 1/Phase 2 | A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors | September 8, 2021 | October 31, 2027 |
| NCT05163028 | Recruiting | Phase 1 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | December 13, 2021 | December 2024 |
| NCT05166070 | Recruiting | Early Phase 1 | An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | January 1, 2022 | January 1, 2037 |
| NCT05173142 | Recruiting | Phase 1/Phase 2 | HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors | January 22, 2022 | August 2025 |
| NCT05174585 | Recruiting | Phase 1/Phase 2 | JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | August 18, 2022 | March 2026 |
| NCT05175235 | Recruiting | Phase 1/Phase 2 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | August 19, 2021 | August 1, 2023 |
| NCT05176483 | Recruiting | Phase 1 | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors | December 14, 2021 | May 2026 |
| NCT05176509 | Recruiting | Phase 1 | A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors | April 5, 2022 | December 2024 |
| NCT05192174 | Recruiting | Phase 1 | Study of NIB101 in Participants With Advanced Solid Tumors | January 24, 2022 | February 29, 2028 |
| NCT05198752 | Recruiting | Phase 1 | A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors | March 18, 2022 | June 12, 2024 |
| NCT05206942 | Recruiting | N/A | Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy | March 21, 2022 | February 28, 2026 |
| NCT05207787 | Recruiting | Phase 1/Phase 2 | Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors | November 9, 2021 | December 31, 2025 |
| NCT03970382 | Suspended | Phase 1 | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | July 3, 2019 | August 12, 2022 |
| NCT04276376 | Suspended | Phase 2 | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors | April 12, 2019 | April 2025 |
| NCT05708924 | Suspended | Phase 1 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | April 28, 2023 | September 30, 2028 |
| NCT05338658 | Suspended | Phase 1 | Study of PAT in Patients With Solid Tumor Cancers | May 19, 2023 | January 2027 |
| NCT03842865 | Temporarily not available | Expanded Access of Vigil in Solid Tumors | |||
| NCT02840110 | Terminated | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product | October 2016 | February 23, 2021 | |
| NCT03182673 | Terminated | Phase 1 | The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors | July 24, 2017 | June 12, 2019 |
| NCT02541604 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | November 30, 2015 | June 6, 2019 |
| NCT01804530 | Terminated | Phase 1 | Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | August 2013 | January 24, 2018 |
| NCT02003092 | Terminated | Phase 1/Phase 2 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | August 2013 | November 2019 |
| NCT02920996 | Terminated | Phase 2 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | November 11, 2016 | October 2023 |
| NCT04810208 | Terminated | Phase 1 | Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours | February 28, 2019 | October 7, 2021 |
| NCT04171700 | Terminated | Phase 2 | A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | January 16, 2020 | July 15, 2022 |
| NCT03600467 | Terminated | Phase 2 | Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma | August 13, 2018 | February 28, 2021 |
| NCT04111107 | Terminated | Phase 2 | Precision Medicine for Patients With Identified Actionable Mutations | April 22, 2020 | February 9, 2023 |
| NCT00512798 | Terminated | Phase 1/Phase 2 | Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | June 2003 | March 2008 |
| NCT04105777 | Terminated | Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Requiring PN (PEKANNUSS) | January 30, 2020 | January 31, 2023 | |
| NCT03894540 | Terminated | Phase 1 | Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | March 22, 2019 | December 21, 2020 |
| NCT04099277 | Terminated | Phase 1 | A Study of LY3435151 in Participants With Solid Tumors | October 28, 2019 | March 5, 2020 |
| NCT00982657 | Terminated | Phase 2 | A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma | September 2009 | March 2014 |
| NCT02548390 | Terminated | Phase 1 | Study of Intravenous RXDX-107 in Patients With Solid Tumors | September 2015 | September 2016 |
| NCT03182257 | Terminated | Phase 1 | Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors | July 12, 2017 | January 30, 2018 |
| NCT04348916 | Terminated | Phase 1 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | May 20, 2020 | May 31, 2023 |
| NCT04071756 | Terminated | Phase 2 | Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions | December 30, 2019 | July 14, 2022 |
| NCT02472977 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | July 13, 2015 | January 27, 2017 |
| NCT04393454 | Terminated | Phase 2 | Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | June 3, 2020 | May 16, 2023 |
| NCT03875313 | Terminated | Phase 1/Phase 2 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | May 20, 2019 | July 29, 2020 |
| NCT00898027 | Terminated | Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer | May 2006 | February 2009 | |
| NCT01929941 | Terminated | Phase 1 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | September 2013 | August 2014 |
| NCT02593708 | Terminated | Phase 1 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | November 3, 2015 | July 31, 2017 |
| NCT00424645 | Terminated | Phase 1/Phase 2 | Voraxaze for Delayed Methotrexate Clearance | January 2007 | January 2008 |
| NCT04013217 | Terminated | Phase 1 | Evaluate Eribulin ORA in Subjects With Solid Tumors | July 29, 2019 | March 2, 2022 |
| NCT01641575 | Terminated | Phase 1 | A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin | July 2012 | June 2013 |
| NCT04586335 | Terminated | Phase 1 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | September 28, 2020 | February 15, 2023 |
| NCT02653196 | Terminated | Early Phase 1 | A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | September 2015 | August 2017 |
| NCT03511222 | Terminated | Phase 1 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | September 11, 2018 | May 28, 2020 |
| NCT01553071 | Terminated | Phase 1 | Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies | November 2016 | December 2020 |
| NCT03637803 | Terminated | Phase 1/Phase 2 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | January 10, 2019 | May 8, 2023 |
| NCT02393248 | Terminated | Phase 1/Phase 2 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | February 27, 2015 | December 17, 2021 |
| NCT04301011 | Terminated | Phase 1/Phase 2 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | June 2, 2020 | January 23, 2023 |
| NCT02950103 | Terminated | Phase 2 | Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients | August 2016 | September 2019 |
| NCT04209465 | Terminated | Phase 1/Phase 2 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | December 19, 2019 | September 16, 2022 |
| NCT03588039 | Terminated | Phase 1 | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | October 25, 2018 | May 12, 2023 |
| NCT03139370 | Terminated | Phase 1 | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | December 27, 2017 | June 4, 2023 |
| NCT00469937 | Terminated | Phase 1 | Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases | February 2006 | March 2009 |
| NCT03834220 | Terminated | Phase 2 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | March 22, 2019 | January 4, 2022 |
| NCT03815682 | Terminated | Phase 1 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | October 24, 2018 | October 11, 2022 |
| NCT03592264 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors | June 7, 2018 | March 21, 2024 |
| NCT02624388 | Terminated | Phase 2 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | August 2016 | September 2021 |
| NCT03993379 | Terminated | Phase 2 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | November 20, 2019 | May 21, 2020 |
| NCT03992131 | Terminated | Phase 1/Phase 2 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | June 28, 2019 | April 22, 2022 |
| NCT00354523 | Terminated | Phase 1/Phase 2 | Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma | December 2004 | August 2013 |
| NCT01981187 | Terminated | Phase 2 | LGX818 for Patients With BRAFV600 Mutated Tumors | January 14, 2014 | October 13, 2015 |
| NCT02663518 | Terminated | Phase 1 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | January 28, 2016 | November 23, 2022 |
| NCT02160041 | Terminated | Phase 2 | BGJ398 for Patients With Tumors With FGFR Genetic Alterations | July 24, 2014 | April 30, 2018 |
| NCT04347226 | Terminated | Phase 2 | Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 | April 16, 2020 | March 1, 2021 |
| NCT03343613 | Terminated | Phase 1 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | November 17, 2017 | May 4, 2020 |
| NCT03333031 | Terminated | Phase 1 | A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies | August 10, 2018 | September 7, 2022 |
| NCT04671901 | Terminated | Phase 2 | A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors | December 10, 2020 | March 29, 2023 |
| NCT03804515 | Terminated | Phase 1 | A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib | June 25, 2019 | June 17, 2020 |
| NCT03770494 | Terminated | Phase 1 | A Study of LY3405105 in Participants With Advanced Cancer | January 31, 2019 | February 4, 2021 |
| NCT00512460 | Terminated | Phase 1 | RTA 744 Injection in Patients With Leptomeningeal Disease | September 2006 | March 2010 |
| NCT01065805 | Terminated | Phase 1/Phase 2 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | March 20, 2009 | February 25, 2019 |
| NCT05221385 | Terminated | Phase 1 | Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma | April 12, 2021 | October 27, 2023 |
| NCT02966171 | Terminated | Phase 1 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | January 2017 | August 23, 2018 |
| NCT03752177 | Terminated | Phase 1 | A Study of LY3415244 in Participants With Advanced Solid Tumors | November 22, 2018 | October 9, 2019 |
| NCT02608307 | Terminated | Medical Treatment Decision Making Using Adaptive Conjoint Analysis | February 9, 2016 | October 17, 2019 | |
| NCT04675996 | Terminated | Phase 1 | First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors | December 18, 2020 | March 24, 2023 |
| NCT05120375 | Terminated | Phase 1 | Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China | February 17, 2022 | April 7, 2023 |
| NCT03680560 | Terminated | Phase 1 | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | March 13, 2019 | March 12, 2020 |
| NCT04250597 | Terminated | Phase 1 | Study of GNX102 in Patients With Advanced Solid Tumors | July 29, 2020 | July 26, 2023 |
| NCT04683939 | Terminated | Phase 1/Phase 2 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | January 18, 2022 | July 24, 2023 |
| NCT02737072 | Terminated | Phase 1 | A Study of LY2510924 and Durvalumab in Participants With Solid Tumors | September 2016 | September 25, 2017 |
| NCT04242147 | Terminated | Phase 1 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors | March 6, 2023 | December 1, 2023 |
| NCT05581719 | Terminated | Phase 1/Phase 2 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | November 15, 2022 | April 15, 2024 |
| NCT04696848 | Terminated | Phase 1/Phase 2 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | February 24, 2021 | March 9, 2023 |
| NCT03264092 | Terminated | N/A | Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Tumors. | September 11, 2017 | October 1, 2020 |
| NCT00742105 | Terminated | Phase 1 | Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | November 17, 2008 | December 22, 2009 |
| NCT00689065 | Terminated | Phase 1 | Safety Study of CALAA-01 to Treat Solid Tumor Cancers | May 2008 | September 2012 |
| NCT04729348 | Terminated | Phase 2 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | March 8, 2021 | January 17, 2024 |
| NCT04367467 | Terminated | Effect of PARP Inhibitors on Glomerular Filtration Rate | February 3, 2020 | July 1, 2021 | |
| NCT04172597 | Terminated | Phase 2 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | December 23, 2019 | March 29, 2022 |
| NCT03471286 | Terminated | Phase 1 | A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | June 6, 2019 | July 30, 2021 |
| NCT04775680 | Terminated | Phase 1/Phase 2 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | March 11, 2021 | February 9, 2023 |
| NCT02049281 | Terminated | Phase 1 | A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011) | February 2014 | May 2014 |
| NCT03928314 | Terminated | Phase 1 | Study of ORIC-101 in Combination With Anticancer Therapy | May 2, 2019 | December 4, 2023 |
| NCT04111445 | Terminated | Phase 1 | Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors | August 29, 2019 | April 27, 2021 |
| NCT00881101 | Unknown status | Phase 1 | Clinical Study of Liposomal Paclitaxel in Chinese Patients | April 2009 | December 2009 |
| NCT04348643 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | February 20, 2020 | April 30, 2024 |
| NCT04360317 | Unknown status | Phase 1 | Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer | June 2020 | August 2021 |
| NCT03552406 | Unknown status | Phase 1 | Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors | April 27, 2018 | December 31, 2021 |
| NCT04228406 | Unknown status | Phase 1 | Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 | July 1, 2019 | December 31, 2020 |
| NCT04183764 | Unknown status | Phase 1 | MAX-40279-01 in Patients With Advanced Solid Tumors | November 28, 2019 | December 1, 2022 |
| NCT04407897 | Unknown status | N/A | SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases | October 7, 2019 | April 1, 2023 |
| NCT04179656 | Unknown status | Phase 2 | The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor | December 2019 | December 2022 |
| NCT04413227 | Unknown status | Phase 1 | A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | April 2, 2020 | September 30, 2021 |
| NCT03544723 | Unknown status | Phase 2 | Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. | October 1, 2018 | December 31, 2022 |
| NCT04432649 | Unknown status | Phase 1/Phase 2 | Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 | June 1, 2020 | May 31, 2024 |
| NCT04433494 | Unknown status | Phase 1 | A Study of TY-302 in Patients With Advanced Solid Tumors | December 7, 2020 | December 2023 |
| NCT05228600 | Unknown status | Phase 1 | YL-13027 in Patients With Advanced Solid Tumors | May 17, 2022 | December 1, 2023 |
| NCT04151329 | Unknown status | Phase 1/Phase 2 | A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor | June 21, 2019 | June 30, 2021 |
| NCT04143789 | Unknown status | Phase 1/Phase 2 | Evaluation of AP-002 in Patients With Solid Tumors | September 27, 2019 | April 2021 |
| NCT00300001 | Unknown status | Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes | March 2006 | ||
| NCT04477057 | Unknown status | Phase 1 | PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors | June 21, 2019 | December 31, 2021 |
| NCT04478916 | Unknown status | Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients | December 18, 2019 | May 2022 | |
| NCT02093325 | Unknown status | Phase 3 | A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia | March 2014 | August 2019 |
| NCT04496375 | Unknown status | An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application | November 5, 2020 | December 5, 2020 | |
| NCT04122339 | Unknown status | Phase 1 | MAX-10181 Given Orally to Patients With Advanced Solid Tumor | February 11, 2020 | November 1, 2022 |
| NCT05246995 | Unknown status | Phase 1 | A Phase I Study of IBI325 in Patients With Advanced Solid Tumor | March 23, 2022 | November 23, 2023 |
| NCT03468751 | Unknown status | Phase 1 | Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors | February 14, 2018 | August 31, 2020 |
| NCT05274191 | Unknown status | Phase 2 | An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors | March 4, 2022 | March 15, 2024 |
| NCT04550663 | Unknown status | Phase 1 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | September 25, 2020 | March 25, 2023 |
| NCT04082910 | Unknown status | Phase 1/Phase 2 | Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells | September 15, 2019 | December 30, 2023 |
| NCT04569916 | Unknown status | Phase 2 | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors | September 2020 | May 2023 |
| NCT04571632 | Unknown status | Phase 2 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors | September 22, 2020 | December 2023 |
| NCT04588324 | Unknown status | Phase 1/Phase 2 | Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors | October 10, 2020 | November 30, 2022 |
| NCT04001569 | Unknown status | Phase 1/Phase 2 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | May 14, 2019 | December 31, 2022 |
| NCT05282784 | Unknown status | N/A | Hyperthermia With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors | March 10, 2022 | April 30, 2022 |
| NCT03991559 | Unknown status | Phase 1 | A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas | November 1, 2018 | May 31, 2020 |
| NCT03973450 | Unknown status | Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia | June 15, 2019 | February 28, 2022 | |
| NCT04673396 | Unknown status | Phase 1 | Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor | September 22, 2020 | July 1, 2022 |
| NCT04679038 | Unknown status | Phase 1/Phase 2 | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | March 17, 2021 | October 1, 2023 |
| NCT03960060 | Unknown status | Phase 1 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors | May 16, 2019 | June 30, 2023 |
| NCT04691713 | Unknown status | N/A | CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors | September 1, 2019 | December 1, 2021 |
| NCT03313219 | Unknown status | Phase 1 | Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China | October 11, 2017 | December 2019 |
| NCT03940820 | Unknown status | Phase 1/Phase 2 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | May 2019 | May 2022 |
| NCT04743388 | Unknown status | Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System | January 4, 2021 | December 2022 | |
| NCT04762862 | Unknown status | QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy | February 1, 2021 | December 31, 2021 | |
| NCT03258099 | Unknown status | Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients | December 28, 2017 | December 2019 | |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT05360368 | Unknown status | Phase 1 | HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors | March 30, 2023 | February 28, 2024 |
| NCT04802980 | Unknown status | Phase 1 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | April 28, 2020 | September 2023 |
| NCT04826458 | Unknown status | N/A | Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology | May 4, 2021 | May 2023 |
| NCT04832204 | Unknown status | Phase 2 | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases | March 25, 2021 | April 2024 |
| NCT04841421 | Unknown status | Early Phase 1 | Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors | May 1, 2021 | March 1, 2024 |
| NCT04848493 | Unknown status | National Project on Vaccines, COVID-19 and Frail Patients | April 19, 2021 | April 20, 2022 | |
| NCT04866485 | Unknown status | Phase 1 | A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody | June 14, 2021 | February 2023 |
| NCT04873440 | Unknown status | Phase 1/Phase 2 | An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | May 6, 2021 | May 31, 2023 |
| NCT03879057 | Unknown status | Phase 1 | Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors | December 21, 2018 | December 20, 2021 |
| NCT05369286 | Unknown status | Phase 1 | A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors | April 11, 2022 | August 31, 2023 |
| NCT03168061 | Unknown status | Phase 1/Phase 2 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | June 30, 2017 | July 2020 |
| NCT04905329 | Unknown status | A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations | April 28, 2020 | September 1, 2023 | |
| NCT02414516 | Unknown status | Phase 1 | A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | March 2015 | August 2019 |
| NCT03844438 | Unknown status | Phase 1 | A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors | December 18, 2018 | March 1, 2022 |
| NCT03835949 | Unknown status | Phase 1 | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | July 16, 2019 | June 2022 |
| NCT05390944 | Unknown status | Phase 1 | An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition | June 8, 2022 | July 29, 2022 |
| NCT05391048 | Unknown status | Phase 1 | An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition | June 6, 2022 | July 22, 2022 |
| NCT00657176 | Unknown status | Phase 1 | An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors | March 2008 | June 2009 |
| NCT05019794 | Unknown status | Phase 2 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | May 13, 2020 | December 30, 2023 |
| NCT01929486 | Unknown status | Phase 1 | Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer. | February 2013 | |
| NCT03815630 | Unknown status | Early Phase 1 | A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors | February 1, 2019 | February 1, 2021 |
| NCT03815084 | Unknown status | Early Phase 1 | A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors | February 1, 2019 | February 1, 2021 |
| NCT05046847 | Unknown status | Phase 1 | A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors | November 30, 2021 | December 2022 |
| NCT02992210 | Unknown status | Phase 1/Phase 2 | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | May 2016 | December 2020 |
| NCT02968485 | Unknown status | Phase 1 | Phase I Study of SHR7390 in Patients With Advanced Solid Tumors | November 2016 | July 2019 |
| NCT01315431 | Unknown status | Phase 1 | A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors | March 2011 | October 2012 |
| NCT02255292 | Unknown status | Phase 2 | A Study: Pure CBD as Single-agent for Solid Tumor. | November 2014 | July 2015 |
| NCT03757936 | Unknown status | Phase 1 | A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors | November 27, 2018 | December 27, 2020 |
| NCT05109832 | Unknown status | Phase 1 | A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects | October 30, 2021 | June 30, 2022 |
| NCT03710265 | Unknown status | Phase 1 | SHR-1701 in Metastatic or Locally Advanced Solid Tumors | November 20, 2018 | December 31, 2022 |
| NCT03673787 | Unknown status | Phase 1/Phase 2 | A Trial of Ipatasertib in Combination With Atezolizumab | August 13, 2018 | November 2023 |
| NCT05136937 | Unknown status | Phase 1 | A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors | November 1, 2021 | June 1, 2023 |
| NCT02963168 | Unknown status | Phase 1 | A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies | April 20, 2017 | April 30, 2020 |
| NCT02575638 | Unknown status | Phase 1 | Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) | July 2008 | February 1, 2020 |
| NCT03596593 | Unknown status | N/A | Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors | July 11, 2018 | June 2020 |
| NCT01806376 | Unknown status | Phase 1 | A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics | March 2013 | September 2014 |
| NCT05196360 | Unknown status | Phase 1 | MAX-10181 in Patients With Advanced Solid Tumor | August 11, 2021 | May 1, 2023 |
| NCT03583125 | Unknown status | Phase 1 | Study of EOC317 in Chinese Patients With Advanced Solid Tumors | May 29, 2018 | November 29, 2020 |
| NCT03166904 | Withdrawn | Phase 2 | Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy | March 2018 | July 31, 2018 |
| NCT05165849 | Withdrawn | Phase 1/Phase 2 | A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors | April 2022 | May 11, 2022 |
| NCT04316169 | Withdrawn | Phase 1 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | October 21, 2021 | January 2028 |
| NCT03905538 | Withdrawn | Early Phase 1 | Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors | August 13, 2019 | December 2024 |
| NCT00820768 | Withdrawn | Phase 1 | A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies | April 1, 2012 | April 1, 2014 |
| NCT05284214 | Withdrawn | Phase 2 | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors | January 2024 | September 2025 |
| NCT00499668 | Withdrawn | N/A | Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer | August 2007 | March 2008 |
| NCT04809012 | Withdrawn | Phase 2 | Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors | June 2021 | June 2024 |
| NCT03906643 | Withdrawn | Phase 1 | HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies | July 15, 2020 | February 20, 2023 |
| NCT02656849 | Withdrawn | Phase 2 | BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors | February 2016 | May 2023 |
| NCT05181865 | Withdrawn | Phase 1/Phase 2 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | January 2022 | January 18, 2022 |
| NCT00753740 | Withdrawn | Phase 2 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | September 2008 | May 2010 |
| NCT03448211 | Withdrawn | Phase 1 | A Study of PTS for Patients With Solid Tumors | May 1, 2018 | August 1, 2019 |
| NCT02101164 | Withdrawn | Phase 4 | Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease | November 2014 | November 2014 |
| NCT00624962 | Withdrawn | N/A | Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors | March 2006 | January 2008 |
| NCT05039931 | Withdrawn | Phase 1 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | September 15, 2021 | June 2023 |
| NCT01007422 | Withdrawn | Opioids Titration in Hospice Patients | June 2008 | May 2009 | |
| NCT03147976 | Withdrawn | Phase 2 | QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors | May 2, 2018 | August 23, 2019 |
| NCT03166176 | Withdrawn | Phase 2 | Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy | March 2018 | July 31, 2018 |